What is MS Phase 3 Study Laquinimod BRAVO?

Category: Others


See also: Clinical Trial

NCT00605215 is a multinational, randomized, parallel-group study performed in subjects with RRMS to assess the efficacy, safety and tolerability of laquinimod over placebo in a double-blind design and a reference arm of interferon β-1a. Other study IDs include: MS-LAQ-302, EUDRACT 2007-005450-23.

Last updated:
There are no evaluations for MS Phase 3 Study Laquinimod BRAVO.